Venture capital firm Frazier Healthcare Partners has spun out a US-based antibiotics developer with the help of grant funding from a Boston University-operated body and a $8.5m series A round.
Healthcare-focused venture capital firm Frazier Healthcare Partners has spun out US-based antibiotics developer Recida Therapeutics with a grant from Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (Carb-X), an international research funding body operated by Boston University. Carb-X’s award of up to $4.4m will complement capital from Recida’s $8.5m series A financing round, led by Frazier Healthcare Partners…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
